Czech Medical Breakthrough: SÚKL Approves Clinical Trial by H₂ Medical Technologies. A New Era Begins in the Fight Against Alzheimer’s Disease.
The decision by SÚKL represents a breakthrough not only for Czech science, but also for European biotechnological research. The study is the first of its kind in Europe and at the same time one of the first fully and officially approved clinical trials worldwide to focus on non-invasive inhalation of molecular hydrogen as a neuroprotective approach.
A Japanese Patent Brought into Czech Clinical Practice
The project builds on previous successful research conducted in Japan under the leadership of Professor Shigeo Ohta, who is globally recognized as the founder of therapeutic molecular hydrogen research. This Czech study is unique in that it is the only one in the world directly based on a patent personally transferred by Professor Ohta, as co-founder, to H₂ Global Group.
The patent, titled “Prophylactic or therapeutic agent for dementia” (EP 3701956 B1), describes the use of gaseous hydrogen as a therapeutic agent for dementia, specifically of the Alzheimer’s type.
“The approval of a clinical study project based on Professor Ohta’s patent is both a great honor and a major responsibility for us. This step confirms that Czech research and innovation are truly world-class,”
says PharmDr. Milan Krajíček, Co-Founder of H₂ Global Group.
New Hope for the Prevention and Supportive Treatment of Alzheimer’s Disease
“Although the first drugs slowing the progression of Alzheimer’s disease have been approved in recent years, there is still no widely available, safe, and effective solution. Our goal is to offer patients and physicians a therapy that is patient-friendly, non-invasive, accessible, safe, and effective,”
says David Maršálek, Founder and CEO of H₂ Global Group.
The clinical study will commence in January 2026 in cooperation with one of the leading neurological centers in the Czech Republic, under the leadership of Professor MUDr. David Školoudík, Ph.D., and will last approximately six months. The objective is to prepare the registration of the world’s first medical device based on molecular hydrogen.
About H₂ Global Group
H₂ Global Group is a European innovation group that integrates research, development, manufacturing, and the practical, functional, and safe application of molecular hydrogen-based technologies.
The group focuses on the professional and wholesale markets, delivering high-quality products and devices for healthcare, wellness, sports, cosmetics, and veterinary medicine. It collaborates with physicians, therapists, scientists, and research institutions worldwide.
Beyond innovative technologies, the company provides expert support, scientific infrastructure, and long-term partnerships, helping to establish new standards of healthcare and preventive medicine.
Under the leadership of David Maršálek and his team, H₂ Global Group has built a unique ecosystem of companies, spanning from research and development to production and global distribution of molecular hydrogen products. With a company valuation exceeding USD 77 million and a growing portfolio of patents and international activities, the group ranks among the most progressive European biotechnology companies.
Today, investors stand at the threshold of a new era of medicine, with the opportunity to become part of a project that unites scientific advancement, social responsibility, and the vision of a longer, healthier, and higher-quality life.
More information:
🌐 www.H2Global.group